Bispecific Antibody Market By Product (Blinatumomab, Emicizumab, Others), By Applications (Cancer, Hemophilia, Others), By End User (Hospitals, Cancer Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Bispecific Antibody Market," The bispecific antibody market was valued at $5.5 billion in 2022, and is estimated to reach $109.4 billion by 2032, growing at a CAGR of 34.8% from 2023 to 2032.

A bispecific antibody, known as bsAb, is an artificial antibody molecule that is engineered for attachment of two separate target antigens at the same time. Traditional antibodies are generally monospecific, which means they are expected to attach to one antigen only. On the other hand, bispecific antibodies have two antigen-binding sites, permitting them to recognize and attach to two distinct targets. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy and for the treatment of other diseases cancer, inflammation, viral infection, and autoimmune diseases.

The bispecific antibody market growth is driven by high prevalence rate of cancer as well as auto-immune diseases and advancement in biotechnology and antibody engineering for development of bispecific antibody. In addition, bispecific antibodies have gained attention in the field of oncology. Bispecific antibodies are expected to simultaneously bind to tumor-specific antigens on cancer cells and immune cells, such as T cells. Rise in prevalence of cancer, infectious diseases, and auto-immune diseases are anticipated to drive the growth of the market. For instance, according to American cancer Society, in 2022, estimated number of new cancer cases in the U.S. were around 1,918,030.

Moreover, Bispecific antibodies (bsAbs), with binding specificity for two different target molecules, have recently been developed for a range of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, and tested in clinical trials. Thus, rise in prevalence of autoimmune diseases is anticipated to drive the growth of the market during the forecast period. In addition, rise in demand for bispecific antibodies and high response rate for bispecific antibodies in multiple myeloma drives the growth of the market. For instance, according to American Society of Clinical Oncology (ASCO), in 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the U.S. are expected to be diagnosed with multiple myeloma. As per the same source, an estimated 176,404 people were diagnosed with multiple myeloma in 2020 globally.

Moreover, rise in effectiveness of the bispecific antibody in multiple myeloma boosts the growth of the market. For instance, according to American Association for Cancer Research, in 2023, the patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate.

Moreover, increase in prevalence of breast cancer and rise in demand for bispecific antibodies in treatment of breast cancer is anticipated to drive the growth of the market. For instance, according to the American Cancer Society, in January 2022, an estimated 287,850 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive breast cancer. As per the same source, in 2022, there were more than 3.8 million women with a history of breast cancer in the U.S. In addition, rise in effectiveness of bispecific antibodies in breast cancer treatment drives the growth of the market. For instance, triple negative breast cancer (TNBC) is a kind of breast cancer with a poor prognosis and few treatment options. In October 2021, according to National Library of Medicine, researchers tested the anticancer activity of F7AK3, a bispecific antibody that binds both trophoblast cell surface antigen 2 (TROP2) and CD3 to identify innovative and effective therapeutics for TNBC. Thus, rise in R&D for development of bispecific antibodies is anticipated to boost the market growth.

On the other hand, side effects associated with bispecific antibodies such as cytokine release syndrome, infusion-related reactions, organ toxicity, hematological effects, immunogenicity, and others are anticipated to hamper the growth of the market. Moreover, complex manufacturing processes and regulatory challenges are expected to restrain the growth of the market.

However, increase in demand for medical services in developed countries such as the U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense growth opportunities for the bispecific antibody market during the forecast period.

The bispecific antibody market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into blinatumomab, emicizumab, and others. Others subsegment includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. On the basis of application, the market is divided into cancer, hemophilia, and others. Others subsegment includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. On the basis of end user, the market is divided into hospitals, cancer center, and others. Others subsegment includes research centers and academic institutions.

On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global bispecific antibody market are AbbVie, Pfizer, Portola Pharmaceuticals, Innovent bio, Merus, MacroGenics, Genmab A/S, AstraZeneca, NovImmune S.A., Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Johnson & Johnson. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand the bispecific antibody market share.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bispecific antibody market analysis from 2022 to 2032 to identify the prevailing bispecific antibody market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the bispecific antibody market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global bispecific antibody market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Applications

Others
Cancer
Hemophilia

By End User

Hospitals
Cancer Center
Others

By Product

Blinatumomab
Emicizumab
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa

Key Market Players:

MacroGenics Inc.
AstraZeneca plc
Regeneron Pharmaceuticals, Inc.
Johnson & Johnson
Pfizer Ltd
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Merus
AbbVie Inc

Product Code: A129947

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of chronic diseases
  - 3.4.1.2. Increase in number of product approvals for bispecific antibody
  - 3.4.1.3. Increase in the research and development activities

3.4.2. Restraints
- 3.4.2.1. Side effects of bispecific antibodies treatment

3.4.3. Opportunities
- 3.4.3.1. Rise in number of strategic collaborations and partnerships

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BISPECIFIC ANTIBODY MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Blinatumomab
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Emicizumab
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Cancer
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Hemophilia
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: BISPECIFIC ANTIBODY MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Cancer Center
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: BISPECIFIC ANTIBODY MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Product
- 7.2.3. Market size and forecast, by Applications
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Product
  - 7.2.5.1.3. Market size and forecast, by Applications
  - 7.2.5.1.4. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Product
  - 7.2.5.2.3. Market size and forecast, by Applications
  - 7.2.5.2.4. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Product
  - 7.2.5.3.3. Market size and forecast, by Applications
  - 7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Product
- 7.3.3. Market size and forecast, by Applications
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Product
  - 7.3.5.1.3. Market size and forecast, by Applications
  - 7.3.5.1.4. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Product
  - 7.3.5.2.3. Market size and forecast, by Applications
  - 7.3.5.2.4. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Product
  - 7.3.5.3.3. Market size and forecast, by Applications
  - 7.3.5.3.4. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Product
  - 7.3.5.4.3. Market size and forecast, by Applications
  - 7.3.5.4.4. Market size and forecast, by End User
  - 7.3.5.5. Rest of Europe
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Product
  - 7.3.5.5.3. Market size and forecast, by Applications
  - 7.3.5.5.4. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Product
- 7.4.3. Market size and forecast, by Applications
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Product
  - 7.4.5.1.3. Market size and forecast, by Applications
  - 7.4.5.1.4. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Product
  - 7.4.5.2.3. Market size and forecast, by Applications
  - 7.4.5.2.4. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Product
  - 7.4.5.3.3. Market size and forecast, by Applications
  - 7.4.5.3.4. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Product
  - 7.4.5.4.3. Market size and forecast, by Applications
  - 7.4.5.4.4. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Product
  - 7.4.5.5.3. Market size and forecast, by Applications
  - 7.4.5.5.4. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Product
  - 7.4.5.6.3. Market size and forecast, by Applications
  - 7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Product
- 7.5.3. Market size and forecast, by Applications
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Latin America
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Product
  - 7.5.5.1.3. Market size and forecast, by Applications
  - 7.5.5.1.4. Market size and forecast, by End User
  - 7.5.5.2. Middle East
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Product
  - 7.5.5.2.3. Market size and forecast, by Applications
  - 7.5.5.2.4. Market size and forecast, by End User
  - 7.5.5.3. Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Product
  - 7.5.5.3.3. Market size and forecast, by Applications
  - 7.5.5.3.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Johnson & Johnson
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. F. Hoffmann-La Roche Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. AbbVie Inc
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Pfizer Ltd
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. AstraZeneca plc
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Merus
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. MacroGenics Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
9.8. Regeneron Pharmaceuticals, Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Bristol-Myers Squibb Company
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Amgen Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments